Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Blood cancers occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Treatment for blood cancer depends on the type of cancer, age, how fast the cancer is progressing, where the cancer has spread and other factors. Some common blood cancer treatments include stem cell transplantation, chemotherapy and radiation therapy. Biopharmaceutical research companies are currently developing 247 medicines targeting leukemia, lymphoma, myeloma and other blood cancers. These medicines are either in human clinical trials or under review by the U.S. Food and Drug Administration (FDA). Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses a patient’s own genetically modified T cells to find and kill cancer. Some of the FDA-approved CAR T-cell therapies are as follows.
KYMRIAH (tisagenlecleucel) is an FDA-approved CAR T-cell therapy for:
i. Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
ii. Young adult patients up to age 25 with relapsed or refractory acute lymphoblastic leukemia (ALL)
YESCARTAT (axicabtagene ciloleucel) is the first FDA-approved CAR T-cell therapy for adult patients with certain types of B-cell lymphoma. The FDA has approved this treatment for patients with the following conditions that have either not responded to or have relapsed following two or more lines of systemic therapy:
i. Diffuse large B-cell lymphoma (DLBCL)
ii. Primary mediastinal B-cell lymphoma
iii. High grade B-cell lymphoma
DLBCL that results from follicular lymphoma
The global blood cancer therapeutics market is observing significant growth owing to high incidence and prevalence of blood cancer, advancements in pharmacology and molecular biology to promote drug development and increasing investments in R&D by the pharmaceutical companies. The market is further boosted by global rise in the incidence of AML, along with increased mortality due to the disease. In addition, increasing per capita income is enabling people to take up advanced procedures, thus driving the growth of this market. Active role of healthcare agencies and government in creating awareness about various diseases is also expected to facilitate the growth of blood cancer therapeutics, thereby supporting market development. However, the market is hindered by complications related to chemotherapy and stringent regulations on drugs.
The report analyses the global blood cancer therapeutics market based on indication, treatment type, end user and geography.
Based on indication, the market is categorized into undifferentiated chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML). Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells in the bone marrow. CLL mainly affects older adults, and accounts for about one-third of all leukemias.
The blood cancer therapeutics market offers treatment types including chemotherapy, radiation therapy, immunotherapy, stem cell transplant, targeted therapy and other treatment types. Stem cell transplants are most often used to help people with leukemia and lymphoma. They may also be used for neuroblastoma and multiple myeloma. The high doses of cancer treatment before a stem cell transplant can cause problems such as bleeding and an increased risk of infection.
Furthermore, various end users of this market are categorized into hospitals, ambulatory surgical centers, oncology centers and clinics. The hospitals comprise surgical units based in hospitals or attached to hospitals that are equipped with instruments and accessories, to perform procedures for diagnostic or treatment of blood cancer.
By geography, the global blood cancer therapeutics market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. In 2018, North America held the largest revenue share mainly due to factors such as government support for quality healthcare, high purchasing power parity, availability of reimbursement, and increasing prevalence of cancers in U.S. and Canada. Furthermore, Asia Pacific is expected to witness lucrative growth over the forecast period owing to supportive government initiatives and improving healthcare infrastructure. Additionally, economic developments in countries, such as India and China, are expected to help spur the market growth. Huge population base with low per capita income in the region led to high demand for affordable treatment options.
The leading blood cancer therapeutics market players are AbbVie Inc, Amgen Inc., Astrazeneca Plc, Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb Co., Celgene Corp., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Glaxosmithkline Plc, Janssen Global Services LLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., PharmaMar, Surface Oncology and Teva Pharmaceutical Industries Ltd. For instance, August 2017, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) approval of BESPONSA (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
The global blood cancer therapeutics market is segmented based on indication, treatment type, end user and geography. Based on indication, the market is categorized into undifferentiated chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML).
The blood cancer therapeutics market offers treatment types including chemotherapy, radiation therapy, immunotherapy, stem cell transplant, targeted therapy and other treatment types. Stem cell transplants are most often used to help people with leukemia and lymphoma.
Furthermore, various end users of this market are categorized into hospitals, ambulatory surgical centers, oncology centers and clinics. Furthermore, various end users of this market are categorized into hospitals, ambulatory surgical centers, oncology centers and clinics.
By geography, the global blood cancer therapeutics market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world. In 2018, North America held the largest revenue share mainly due to factors such as government support for quality healthcare, high purchasing power parity, availability of reimbursement, and increasing prevalence of cancers in U.S. and Canada.
Why to buy this report:
